# Hospital Universitario Puerta de Hierro Majadahonda

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-universitario-puerta-de-hierro-majadahonda/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 55 |
| Citations | 769,572 |
| City | Madrid |
| Country | ES |
| Description | Hospital Universitario Puerta de Hierro Majadahonda is a research organisation in Madrid, ES. OpenAlex records 15,574 works and 769,572 citations for it. 5,056 researchers list it as their most recent affiliation. |
| Homepage | https://www.comunidad.madrid/hospital/puertadehierro/ |
| OpenAlex ID | https://openalex.org/I4210105637 |
| Researchers | 5,056 |
| ROR ID | https://ror.org/01e57nb43 |
| Type | healthcare |
| Works | 15,574 |

## University papers

Showing 12 of 19.

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report](https://scholariq.org/papers/national-institutes-of-health-consensus-development-project-on-criteria-for/)
- [Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation](https://scholariq.org/papers/letermovir-prophylaxis-for-cytomegalovirus-in-hematopoietic-cell-transplantation/)
- [Perioperative Nivolumab in Resectable Lung Cancer](https://scholariq.org/papers/perioperative-nivolumab-in-resectable-lung-cancer/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)](https://scholariq.org/papers/covid-19-infection-in-adult-patients-with-hematological-malignancies-a-european/)
- [Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-in/)
- [Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion](https://scholariq.org/papers/complement-factor-i-deficiency-a-not-so-rare-immune-defect-characterization-of/)
- [SERPING1 mutations in 59 families with hereditary angioedema](https://scholariq.org/papers/serping1-mutations-in-59-families-with-hereditary-angioedema/)
- [Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome](https://scholariq.org/papers/complement-factor-h-fhr-3-and-fhr-1-variants-associate-in-an-extended-haplotype/)
- [A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation](https://scholariq.org/papers/a-new-case-of-homozygous-c1-inhibitor-deficiency-suggests-a-role-for-arg378-in/)

## University researchers

- [Sofía Garrido](https://scholariq.org/researchers/sofia-garrido/)

## University top topics

Showing 8 of 25.

- [Transplantation: Methods and Outcomes](https://scholariq.org/topics/transplantation-methods-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Organ Transplantation Techniques and Outcomes](https://scholariq.org/topics/organ-transplantation-techniques-and-outcomes/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Cardiac Structural Anomalies and Repair](https://scholariq.org/topics/cardiac-structural-anomalies-and-repair/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.